Myriad Genetics, Inc. (NASDAQ:MYGN) VP Richard M. Marsh sold 37,654 shares of the stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $40.25, for a total value of $1,515,573.50. Following the sale, the vice president now owns 157,648 shares of the company’s stock, valued at approximately $6,345,332. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Shares of Myriad Genetics, Inc. (NASDAQ MYGN) traded up $1.26 during trading hours on Monday, reaching $39.88. 1,171,895 shares of the company’s stock traded hands, compared to its average volume of 703,162. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34. Myriad Genetics, Inc. has a 52 week low of $15.15 and a 52 week high of $40.36. The firm has a market cap of $2,760.00, a P/E ratio of 26.95, a P/E/G ratio of 2.45 and a beta of 0.24.
Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.05. Myriad Genetics had a net margin of 13.28% and a return on equity of 9.54%. The company had revenue of $190.20 million for the quarter, compared to the consensus estimate of $183.52 million. During the same period in the previous year, the business earned $0.23 EPS. The company’s revenue was up 7.2% on a year-over-year basis. analysts expect that Myriad Genetics, Inc. will post 1.05 EPS for the current year.
A number of brokerages have recently commented on MYGN. Zacks Investment Research upgraded Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 price objective for the company in a research report on Tuesday, October 17th. BTIG Research set a $41.00 price objective on Myriad Genetics and gave the company a “buy” rating in a research report on Tuesday, January 16th. Morgan Stanley reiterated an “underweight” rating and set a $24.00 price objective (up previously from $17.00) on shares of Myriad Genetics in a research report on Friday, October 6th. ValuEngine downgraded Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Finally, BidaskClub upgraded Myriad Genetics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $30.55.
TRADEMARK VIOLATION NOTICE: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/22/myriad-genetics-inc-mygn-vp-sells-1515573-50-in-stock.html.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.